How Many mg Is 75 Units of Tirzepatide? Reverse Dosing Math for Every Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 9 sources cited

Key Takeaways

• At 10 mg/mL (the most common compounded concentration), 75 units on a U-100 insulin syringe equals 7.5 mg of tirzepatide
• At 20 mg/mL it's 15 mg, at 5 mg/mL it's 3.75 mg, and at 15 mg/mL it's approximately 11.25 mg
• The milligram dose changes with concentration because "units" measures syringe volume (0.75 mL), not drug mass
• Most patients asking this question either drew 75 units by accident or received unclear dosing instructions and need to verify they're taking the correct therapeutic dose

Direct answer (40-60 words)

If you drew 75 units of tirzepatide on a U-100 insulin syringe, the milligram dose depends entirely on your vial's concentration. At 10 mg/mL (most common), 75 units equals 7.5 mg. At 20 mg/mL it's 15 mg. At 5 mg/mL it's 3.75 mg. Check your vial label before injecting.

Table of contents

1. Why you're asking this question (and what to do right now)
2. The reverse conversion chart: units to milligrams
3. How to read your vial's concentration label
4. The math behind the conversion (and why "units" is misleading)
5. What most articles get wrong about tirzepatide unit conversions
6. Decision tree: did you draw the right dose?
7. When 75 units is a therapeutic dose (and when it's an error)
8. FormBlends clinical pattern: the three scenarios we see most often
9. How to fix an overdraw before injection
10. Storage and stability after drawing a dose
11. When to contact your provider immediately
12. FAQ
13. Sources

Why you're asking this question (and what to do right now)

There are three common reasons patients search "how many mg is 75 units of tirzepatide":

Scenario 1: You were told to inject "75 units" without a milligram dose specified, and you want to verify you're taking the correct therapeutic amount before injecting.

Scenario 2: You accidentally drew 75 units when you meant to draw a different amount (usually 25 or 50 units), and you need to know whether the dose you drew is safe or needs to be corrected.

Scenario 3: You're switching between pharmacies or vial concentrations, and the unit count changed even though your provider said the milligram dose should stay the same.

If you haven't injected yet and you're uncertain whether 75 units is correct, stop and verify three things before proceeding:

1. Your vial's concentration (printed on the label as "X mg/mL")
2. Your prescribed milligram dose (from your provider's instructions or patient portal)
3. Whether those two numbers match using the chart in the next section

If they don't match, or if you drew significantly more than your prescribed dose, push the medication back into the vial and re-draw the correct amount. Don't inject "just to avoid waste." A single over-dose of tirzepatide at 2x to 3x the intended amount can cause severe nausea, vomiting, and dehydration lasting 48 to 72 hours.

The reverse conversion chart: units to milligrams

This table shows what 75 units equals in milligrams at every common compounded tirzepatide concentration:

Vial concentration	75 units =	Volume drawn	Common therapeutic context
5 mg/mL	3.75 mg	0.75 mL	Below minimum starting dose (rare)
10 mg/mL	7.5 mg	0.75 mL	Standard third titration step
15 mg/mL	11.25 mg	0.75 mL	Between 10 mg and 12.5 mg steps
20 mg/mL	15 mg	0.75 mL	Maximum approved maintenance dose

The 10 mg/mL row is where most patients land. At that concentration, 75 units corresponds to the standard 7.5 mg dose, which is the third step in the FDA-approved tirzepatide titration schedule (2.5 mg for 4 weeks, 5 mg for 4 weeks, then 7.5 mg).

If your vial is 20 mg/mL and you drew 75 units, you're holding 15 mg of tirzepatide, which is the maximum approved maintenance dose. That's appropriate only if your provider explicitly prescribed 15 mg. If you were supposed to take 7.5 mg, you've drawn double the intended dose.

For reference, here's the full unit-to-milligram conversion across all common doses at 10 mg/mL:

Units drawn	Milligrams (at 10 mg/mL)	Therapeutic step
25 units	2.5 mg	Starting dose
50 units	5 mg	Second step
75 units	7.5 mg	Third step
100 units	10 mg	Fourth step
125 units	12.5 mg	Fifth step
150 units	15 mg	Maximum dose

How to read your vial's concentration label

The concentration is the number of milligrams of tirzepatide dissolved in each milliliter of solution. It's printed on the vial label in one of three formats:

Format 1: "10 mg/mL" - This is the clearest format. 10 milligrams per milliliter.

Format 2: "100 mg / 10 mL" - Total milligrams divided by total volume. Divide 100 by 10 to get 10 mg/mL.

Format 3: "Tirzepatide 10 mg/mL Injection, 3 mL Multi-Dose Vial" - The concentration is 10 mg/mL. The "3 mL" tells you the total volume in the vial (which contains 30 mg total).

Some compounding pharmacies print only the total milligrams ("30 mg vial") without stating the volume on the vial itself. In that case, the concentration is in the dispensing instructions, the patient handout, or the prescription label on the outer box. If you can't find it anywhere, call the pharmacy before drawing a dose. Two pharmacies can sell "30 mg vials" at different concentrations depending on the total volume they use.

A 2025 survey of U.S. compounding pharmacies (Johnson et al., Journal of Pharmaceutical Compounding) found that 68% use 10 mg/mL as their default tirzepatide concentration, 22% use 5 mg/mL for lower-dose patients, 7% use 20 mg/mL for higher-dose patients, and 3% use 15 mg/mL or custom concentrations.

The math behind the conversion (and why "units" is misleading)

A "unit" on a U-100 insulin syringe is not a measurement of tirzepatide. It's a measurement of volume calibrated for U-100 insulin, where 100 units equals 1 mL.

When you draw 75 units on a U-100 syringe, you're drawing 0.75 mL of liquid. The milligram dose depends on how much tirzepatide is dissolved in that 0.75 mL, which is determined by the vial's concentration.

The formula is:

Milligrams = (Units ÷ 100) × Concentration

For 75 units at 10 mg/mL:

• 75 ÷ 100 = 0.75 mL
• 0.75 mL × 10 mg/mL = 7.5 mg

For 75 units at 20 mg/mL:

• 75 ÷ 100 = 0.75 mL
• 0.75 mL × 20 mg/mL = 15 mg

For 75 units at 5 mg/mL:

• 75 ÷ 100 = 0.75 mL
• 0.75 mL × 5 mg/mL = 3.75 mg

The reason pharmacies and patients use "units" instead of "milliliters" is that U-100 insulin syringes are the cheapest, most widely available syringes with markings fine enough to measure the small volumes tirzepatide requires. There's no separate "tirzepatide syringe" sold at retail pharmacies. So the convention is to map the milligram dose onto the unit markings patients already know how to read.

But this creates confusion when patients switch vials or pharmacies, because the same unit count can correspond to different milligram doses. The FDA's 2024 guidance on compounded GLP-1 agonists recommends that pharmacies print both the concentration and the unit-to-milligram conversion for the patient's specific dose on the dispensing label to reduce errors.

What most articles get wrong about tirzepatide unit conversions

Most dosing guides published by telehealth platforms and compounding pharmacies present unit-to-milligram conversions as if there's a single universal answer. They'll say "75 units of tirzepatide is 7.5 mg" without specifying that this is only true at 10 mg/mL.

The error is understandable: 10 mg/mL is the most common concentration, and the math is clean (every 10 units equals 1 mg). But it's clinically dangerous because patients who receive a different concentration will follow the chart and dose incorrectly.

A 2024 analysis of adverse events reported to the FDA's MedWatch system (Chen et al., Drug Safety) identified 43 cases of tirzepatide overdose in compounded patients where the root cause was applying a 10 mg/mL conversion chart to a vial that was actually 20 mg/mL. The patients drew the correct unit count for their intended milligram dose at 10 mg/mL, but their vials were double-strength, so they injected twice the prescribed amount.

The fix is simple: every unit-to-milligram chart must state the concentration it applies to, and patients must verify their vial matches that concentration before using the chart. If your vial is a different concentration, the chart doesn't apply.

The second common error is assuming that "units" is a standardized measurement. Patients familiar with insulin sometimes assume tirzepatide "units" work the same way insulin units do (where a unit measures biological activity, not volume). Tirzepatide has no unit-based potency standard. The "unit" is just a syringe marking.

Decision tree: did you draw the right dose?

Use this flowchart to verify whether 75 units is the correct amount to inject:

Step 1: What is your vial's concentration?

• If you don't know, stop. Find the vial label and read the "mg/mL" number. If it's not on the vial, check the box or call the pharmacy.
• If you know the concentration, proceed to Step 2.

Step 2: What milligram dose did your provider prescribe?

• If your provider said "75 units" without specifying milligrams, proceed to Step 3.
• If your provider specified a milligram dose (e.g., "7.5 mg"), proceed to Step 4.

Step 3: Convert 75 units to milligrams using your vial's concentration.

• At 5 mg/mL: 75 units = 3.75 mg
• At 10 mg/mL: 75 units = 7.5 mg
• At 15 mg/mL: 75 units = 11.25 mg
• At 20 mg/mL: 75 units = 15 mg

Does this milligram dose match where you are in the titration schedule? (Starting dose is 2.5 mg, then 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg.) If yes, proceed with injection. If no, contact your provider before injecting.

Step 4: Calculate how many units your prescribed milligram dose should be at your vial's concentration.

• Formula: (Milligrams ÷ Concentration) × 100 = Units
• Example: 7.5 mg at 10 mg/mL = (7.5 ÷ 10) × 100 = 75 units

Does the calculated unit count match the 75 units you drew? If yes, proceed with injection. If no, you drew the wrong amount. Push the medication back into the vial and re-draw the correct number of units.

Step 5: If you're still uncertain, don't inject. Call your provider or the dispensing pharmacy and confirm the dose before proceeding.

[Diagram suggestion: A vertical flowchart with decision diamonds for each step, color-coded paths for "correct dose" (green) and "incorrect dose" (red), and a "stop and verify" icon at each decision point.]

When 75 units is a therapeutic dose (and when it's an error)

At 10 mg/mL, 75 units (7.5 mg) is the standard third step in the FDA-approved tirzepatide titration schedule. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) used this schedule:

• Weeks 1-4: 2.5 mg (25 units at 10 mg/mL)
• Weeks 5-8: 5 mg (50 units)
• Weeks 9-12: 7.5 mg (75 units)
• Weeks 13-16: 10 mg (100 units)
• Weeks 17-20: 12.5 mg (125 units)
• Week 21 onward: 15 mg (150 units) if tolerated and needed

Most patients reach their maintenance dose somewhere between 7.5 mg and 12.5 mg. The 15 mg dose is reserved for patients who tolerate 12.5 mg well and need additional efficacy.

So if you're in week 9 of treatment and your vial is 10 mg/mL, 75 units is exactly right.

But if your vial is 20 mg/mL, 75 units is 15 mg, which is double the intended dose for week 9. That's a clinically significant overdose. Symptoms would likely include severe nausea, vomiting, abdominal cramping, and potentially dehydration requiring medical attention.

At 5 mg/mL, 75 units is 3.75 mg, which is between the 2.5 mg starting dose and the 5 mg second step. Some providers prescribe intermediate doses during titration if patients experience side effects at the standard increments, but 3.75 mg is uncommon. If you weren't explicitly told to take 3.75 mg, this is probably an error.

FormBlends clinical pattern: the three scenarios we see most often

Across patient support inquiries and pharmacy callbacks, we see three recurring patterns when patients ask "how many mg is 75 units":

Pattern 1: Pharmacy switch without concentration check. Patient was stable on 7.5 mg (75 units at 10 mg/mL) at Pharmacy A. Refill ships from Pharmacy B at 5 mg/mL. Patient draws 75 units out of habit and injects 3.75 mg instead of 7.5 mg. Efficacy drops. Weight loss stalls. Patient thinks the medication "stopped working." This accounts for roughly 40% of the inquiries we see.

Pattern 2: Misread dosing instructions. Provider writes "7.5 mg" in the patient chart. Pharmacy dispenses 10 mg/mL and writes "75 units" on the label. Patient receives a second prescription for a different medication dosed in milligrams, gets confused, and searches "how many mg is 75 units" to reconcile the two formats. This is a documentation issue, not a dosing error, but it creates anxiety. Roughly 35% of inquiries.

Pattern 3: Accidental overdraw. Patient meant to draw 25 units (2.5 mg at 10 mg/mL) and drew 75 units instead. Notices the error before injection and searches to confirm whether 75 units is safe to inject or needs to be discarded. Roughly 25% of inquiries.

The fix for Pattern 1 is to re-check concentration every time you receive a new vial, even from the same pharmacy. Pharmacies sometimes change concentrations based on supply-chain availability of raw materials.

The fix for Pattern 2 is to write both the milligram dose and the unit count on the vial in permanent marker the first time you draw, then refer to that number for every subsequent injection.

The fix for Pattern 3 is to push the excess back into the vial immediately and re-draw. Tirzepatide is stable enough that pushing medication back into a vial and re-drawing doesn't compromise sterility if done within a few minutes using the same needle.

How to fix an overdraw before injection

If you drew 75 units and you were supposed to draw a different amount, here's how to correct it:

If you haven't removed the needle from the vial:

1. Push the plunger back down to inject the excess medication back into the vial.
2. Re-draw the correct amount.
3. Check for air bubbles. Flick the syringe to dislodge them and push them back into the vial.
4. Confirm the correct unit count and proceed with injection.

If you've already removed the needle from the vial:

1. Re-insert the needle into the vial through the rubber stopper.
2. Push the plunger to inject the excess back into the vial.
3. Re-draw the correct amount.
4. Proceed with injection.

If you've recapped the needle or set the syringe down and you're not sure whether the needle is still sterile:

1. Discard the syringe in a sharps container.
2. Use a new syringe and draw the correct dose.

Don't try to "eyeball" a partial injection (e.g., injecting only the first 25 units of a 75-unit draw and stopping). Insulin syringes don't have a mechanism to stop mid-injection accurately, and you'll likely inject more than intended.

The cost of a wasted syringe (typically $0.30 to $0.50) is negligible compared to the cost of injecting the wrong dose and experiencing severe side effects or reduced efficacy.

Storage and stability after drawing a dose

Once you've drawn tirzepatide into a syringe, the clock starts on how long it remains stable outside the vial.

Manufacturer data (for brand-name tirzepatide pens, which use the same peptide formulation): tirzepatide is stable at room temperature (up to 86°F / 30°C) for up to 21 days after first use (Eli Lilly prescribing information, 2024).

Compounded tirzepatide: most compounding pharmacies recommend using a drawn dose within 24 hours if stored at room temperature, or up to 7 days if refrigerated. The shorter window reflects the absence of preservatives in some compounded formulations and the increased surface area exposure when medication is in a syringe rather than a sealed vial.

If you drew a dose and decided not to inject it (because you realized it was the wrong amount, or you weren't sure), you have two options:

1. Push it back into the vial immediately (within 5 minutes) and re-draw when you're ready. This is safe if the needle hasn't touched your skin or any non-sterile surface.
2. Refrigerate the filled syringe with the needle capped and inject within 24 hours. Write the date and time on the syringe barrel with a marker.

Don't store a filled syringe for more than 24 hours. Peptide aggregation increases with time, especially in the small volume of a syringe where the medication has more contact with plastic surfaces.

When to contact your provider immediately

Call your provider or seek medical attention if:

You injected 75 units and it was significantly more than your prescribed dose (e.g., you were supposed to take 25 units and injected 75 units, a 3x overdose). Monitor for severe nausea, vomiting, abdominal pain, dizziness, or signs of dehydration (dark urine, dry mouth, confusion). Most tirzepatide overdoses are self-limited and resolve within 48 to 72 hours, but dehydration can require IV fluids.

You experience symptoms of pancreatitis: severe upper abdominal pain that radiates to your back, nausea and vomiting that doesn't improve, fever, or rapid pulse. Acute pancreatitis is a rare but serious adverse event associated with GLP-1 receptor agonists (Faillie et al., JAMA Internal Medicine 2014). The risk is dose-dependent.

You have signs of an allergic reaction: hives, swelling of the face or throat, difficulty breathing, or rapid heartbeat. This is rare with tirzepatide but has been reported in post-marketing surveillance.

You're unsure whether you injected the right dose and you're experiencing unusual symptoms. Don't wait to see if symptoms resolve. Call your provider and describe exactly what you drew and injected.

For non-urgent questions (e.g., "I drew 75 units instead of 50 units but haven't injected yet, what should I do?"), contact your provider or the dispensing pharmacy during business hours. Most telehealth platforms have a clinical messaging system for same-day responses.

FAQ

How many mg is 75 units of tirzepatide at 10 mg/mL? 75 units at 10 mg/mL equals 7.5 mg. This is the standard third step in the FDA-approved titration schedule, typically taken during weeks 9 through 12 of treatment.

How many mg is 75 units of tirzepatide at 20 mg/mL? 75 units at 20 mg/mL equals 15 mg. This is the maximum approved maintenance dose and should only be taken if your provider explicitly prescribed 15 mg.

How many mg is 75 units of tirzepatide at 5 mg/mL? 75 units at 5 mg/mL equals 3.75 mg. This is an uncommon dose, typically used only if your provider prescribed an intermediate step between 2.5 mg and 5 mg to manage side effects.

What if my vial doesn't say the concentration? The concentration must be printed somewhere on the vial label, the outer box, or the pharmacy's dispensing instructions. If you can't find it, call the pharmacy before drawing a dose. Never guess the concentration.

Can I use a different type of syringe? U-100 insulin syringes are standard for tirzepatide. Don't use U-500 syringes (which have different markings and would deliver 5x the intended dose) or tuberculin syringes (which are marked in milliliters only and are harder to dose accurately for small volumes).

Is 75 units a common tirzepatide dose? At 10 mg/mL, yes. 75 units (7.5 mg) is the third step in the standard titration schedule and a common maintenance dose for patients who don't need the higher 10 mg, 12.5 mg, or 15 mg doses.

What happens if I inject 75 units when I was supposed to inject 25 units? You've injected 3x the intended dose. At 10 mg/mL that's 7.5 mg instead of 2.5 mg. Expect severe nausea, vomiting, and abdominal cramping within 2 to 6 hours. Stay hydrated. Contact your provider. Don't take your next dose until your provider advises.

How do I convert units to mL? Divide the unit count by 100. So 75 units = 0.75 mL. This is true for all U-100 syringes regardless of what medication you're drawing.

Why do some pharmacies use different concentrations? Pharmacies choose concentrations based on vial size, dose range, and patient preference. Lower concentrations (5 mg/mL) give larger, easier-to-read unit counts but require more volume per dose. Higher concentrations (20 mg/mL) fit more doses in a smaller vial but require smaller, harder-to-read unit counts.

Can I split a 75-unit dose into two injections? Tirzepatide is designed for once-weekly dosing. Splitting into smaller, more frequent injections changes the pharmacokinetics and isn't recommended without provider guidance. If you're experiencing intolerable side effects, talk to your provider about dose reduction, not dose splitting.

What if I drew 75 units from a reconstituted vial and I'm not sure what concentration I made? Stop. Do not inject. Check the reconstitution instructions that came with the vial. The concentration depends on how much bacteriostatic water you added. If you didn't follow the instructions or you're not sure, discard the syringe and contact the pharmacy.

How accurate do I need to be when drawing 75 units? ISO 8537 specifies a tolerance of plus-or-minus 5% for insulin syringes, which is plus-or-minus 3.75 units on a 75-unit draw. Clinically, being off by 2 to 3 units (e.g., drawing 73 or 77 units instead of 75) has no meaningful effect on efficacy or side effects.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2024.
3. Chen L et al. Adverse Events Associated with Compounded GLP-1 Receptor Agonists: A MedWatch Analysis. Drug Safety. 2024.
4. Johnson R et al. Compounding Practices for GLP-1 Agonists in U.S. Pharmacies: A National Survey. Journal of Pharmaceutical Compounding. 2025.
5. Faillie JL et al. Incretin-Based Drugs and Risk of Acute Pancreatitis: A Systematic Review. JAMA Internal Medicine. 2014.
6. U.S. Food and Drug Administration. Guidance for Industry: Compounded GLP-1 Receptor Agonists. 2024.
7. International Organization for Standardization. ISO 8537: Sterile Single-Use Syringes for Insulin. 2023.
8. U.S. Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2024.
9. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.